Key Developments: Enzo Biochem Inc (ENZ)

ENZ on New York Consolidated

4.48USD
21 Nov 2014
Price Change (% chg)

$0.29 (+6.92%)
Prev Close
$4.19
Open
$4.27
Day's High
$4.54
Day's Low
$4.25
Volume
655,904
Avg. Vol
191,209
52-wk High
$6.13
52-wk Low
$2.29

Search Stocks

Latest Key Developments (Source: Significant Developments)

Enzo Biochem awarded patent for Novel Vectors involving Gene Therapy Treatments for cancer, virus infections and genetic diseases
Tuesday, 7 Oct 2014 09:00am EDT 

Enzo Biochem Inc:Says U.S. Patent and Trademark Office has awarded company Patent No. 8,846,893, covering novel vectors for gene therapy treatments for cancers, virus infections and genetic diseases.  Full Article

Enzo Biochem Inc announces settlement agreement with PerkinElmer Inc
Monday, 23 Jun 2014 07:30am EDT 

Enzo Biochem Inc:Enters into Settlement with PerkinElmer, Inc. and PerkinElmer Health Sciences, Inc. with respect to action between company and PerkinElmer before the U.S. District Court, Southern District of New York, Case No 03-CV-3817.PerkinElmer, Inc. has agreed to pay $7,000,000 in escrow in settlement pursuant to agreement.  Full Article

Enzo Biochem receives U.S. patent on more efficient vector for use in gene therapy
Friday, 6 Jun 2014 08:30am EDT 

Enzo Biochem Inc:Assigned U.S. Patent Office Patent No. 8,742,090, related to the construct of an artificial vector capable of greater efficiency, in general, in targeting specific cells in the application of gene therapy and gene transfer technology.  Full Article

Enzo Biochem unit partners with Innate Pharma S.A. to validate key system for antibody drug conjugate development
Friday, 30 May 2014 08:30am EDT 

Enzo Biochem Inc:Announced that its Life Sciences division has established a collaboration with Innate Pharma S.A. to support a novel application of its ProteoStat(reg) products for antibody-drug conjugate (ADC) design.ADCs are monoclonal antibodies engineered to go unnoticed, delivering cytotoxic drugs to cells expressing the antigen target. Cancer therapy has become the most prevalent application area, with 30 ADCs currently in clinical trials.  Full Article

Enzo Biochem announces settlement agreement with Affymetrix
Thursday, 24 Apr 2014 09:45am EDT 

Enzo Biochem Inc:Enters into settlement with Affymetrix, Inc. with respect to actions between the company and Affymetrix before the U.S. District Court.In settlement of the aforementioned cases, Affymetrix will pay $5,100,000.  Full Article

Enzo Biochem Inc's Clinical Lab and Nuclea Biotechnologies join to market new test for certain high risk breast cancer patients
Tuesday, 18 Feb 2014 09:00am EST 

Enzo Biochem Inc:Says its Enzo Clinical Labs subsidiary and Nuclea Biotechnologies, Inc. have entered into a non-exclusive distribution agreement to market Nuclea`s non-invasive HER-2/neu serum test, a key assay in the monitoring of metastatic breast cancer.Says this blood test facilitates the monitoring and treatment decisions of women with metastatic breast cancer that overexpresses the HER-2/neu protein in the tumor.  Full Article

Federal Court awards Enzo Biochem Inc over $61 mln in patent infringement damages
Monday, 6 Jan 2014 10:40am EST 

Enzo Biochem Inc:Says that a Federal Court Judge in New Haven, CT, in connection with the favorable November 2012 jury finding of direct infringement damages of Enzo patents by Applera Corp., now Life Technologies Inc.Says Federal Court Judge has awarded the company prejudgment interest of $12,428,729, bringing the total award to in excess of $61 million.Says additional post-interest on the full amount was also awarded starting Nov. 7, 2012 until the total judgment is satisfied, which, it is estimated, could add several additional millions.  Full Article

Enzo Biochem Inc Announces Study In Scientific Journal Linking Idiopathic Pulmonary Fibrosis
Friday, 15 Nov 2013 08:30am EST 

Enzo Biochem Inc announced publication of a study in a scientific journal, Modern Pathology, a Nature Publishing Group publication, that shows a strong association of idiopathic pulmonary fibrosis (IPF), a pulmonary disease with 100% mortality within five years, with the presence of the herpesvirus saimiri virus, a virus native to squirrel monkeys. The discovery of the IPF`s origin is expected to result in a clinical diagnostic that could lead to screening and diagnosis, and perhaps result in potential treatment, for this fatal disease. The publication was authored by scientists from Enzo Biochem, Ohio State University, the Medical College of Wisconsin and Cornell University. The discovery is the subject of a patent application that is exclusively assigned to Enzo Biochem. Pulmonary fibrosis affects about one million people in the United States, of which IPF represents about 200,000 cases (20%). There is currently no effective way to diagnose IPF prior to the clinical manifestation of symptoms and treatments are largely ineffective. This new marker for IPF could address the urgent critical requirement for early diagnosis and screening of the pulmonary fibrosis population (over a million subjects). The goal of the study was to evaluate the role of the herpesviruses family in IPF. Researchers used 21 paraffin embedded lung biopsies from patients diagnosed with IPF, and 21 lung biopsies from age matched controls with pulmonary fibrosis that is not IPF.  Full Article

Enzo Biochem Inc Enters Into USD8 Million Senior Secured Revolving Credit Facility With Healthcare Finance Group, LLC
Tuesday, 11 Jun 2013 07:00am EDT 

Enzo Biochem, Inc. announced that it has arranged an $8 million senior secured revolving line of credit that may be increased to $12 million with Healthcare Finance Group, LLC (HFG), of New York, New York, that may be utilized for working capital and growth purposes. The new secured revolving line of credit will provide for advances against eligible receivables, as defined, of the Clinical Labs and Life Sciences segments.  Full Article

Search Stocks